INTERVENTIONAL VASCULAR CORPORATE PRESS RELEASES

Please find below a list of our press releases.

25 Jul 2013

BTG Announces Positive Results from VANISH-2 Study Data Published in the Journal Phlebology

BTG, the specialist healthcare company, today announced the online publication of VANISH-2, a study in which patients with symptomatic and visible varicose veins caused by saphenofemoral junction (SFJ) incompetence were treated with polidocanol endovenous microfoam (PEM).

8 Jul 2013

BTG PLC acquisition of EKOS

On 23 May 2013, BTG plc (BTG or the Company), the specialist healthcare company, announced that it had entered into an agreement to buy EKOS Corporation (EKOS) conditional on Hart-Scott-Rodino (HSR) approval in the US.

23 May 2013

BTG PLC acquisition of EKOS

BTG plc is pleased to announce that it has entered into an agreement to buy EKOS Corporation.

12 Apr 2013

BTG plc: Varisolve® NDA accepted for full review by FDA

BTG plc, announces that the New Drug Application (NDA) seeking approval of Varisolve® as a comprehensive treatment for varicose veins, which was submitted to the US Food & Drug Administration (FDA) on 4 February 2013, has been accepted for full review by the FDA.

4 Feb 2013

BTG plc: Varisolve® NDA submitted to the FDA

BTG plc today announces that a New Drug Application (NDA) seeking approval of Varisolve® (polidocanol endovenous microfoam (PEM)) as a comprehensive treatment for varicose veins has been submitted to the US Food & Drug Administration (FDA).